|
1
|
Ferlay J, Steliarova-Foucher E,
Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and
Bray F: Cancer incidence and mortality patterns in Europe:
Estimates for 40 countries in 2012. Eur J Cancer. 49:1374–1403.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Utzschneider S, Wicherek E, Weber P,
Schmidt G, Jansson V and Dürr HR: Surgical treatment of bone
metastases in patients with lung cancer. Int Orthop. 35:731–736.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ávila-Moreno F, Armas-López L,
Álvarez-Moran AM, López-Bujanda Z, Ortiz-Quintero B,
Hidalgo-Miranda A, Urrea-Ramírez F, Rivera-Rosales RM,
Vázquez-Manríquez E, Peña-Mirabal E, et al: Overexpression of MEOX2
and TWIST1 is associated with H3K27me3 levels and determines lung
cancer chemoresistance and prognosis. PLoS One. 9:e1141042014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tan C, Chen H and Wu T: Classification
models for detection of lung cancer based on nine element
distribution of urine samples. Biol Trace Elem Res. 142:18–28.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ironmonger L, Ohuma E, Ormiston-Smith N,
Gildea C, Thomson CS and Peake MD: An evaluation of the impact of
large-scale interventions to raise public awareness of a lung
cancer symptom. Br J Cancer. 112:207–216. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang N, Su Y and Xu L: Targeting PKCε by
miR-143 regulates cell apoptosis in lung cancer. FEBS Lett.
587:3661–3667. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Han SW and Roman J: Targeting apoptotic
signaling pathways in human lung cancer. Curr Cancer Drug Targets.
10:566–574. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Van K, euren-Jensen KR, Malenica I,
Courtright AL, Ghaffari LT, Starr AP, Metpally RP, Beecroft TA,
Carlson EW, Kiefer JA, Pockros PJ and Rakela J: microRNA changes in
liver tissue associated with fibrosis progression in patients with
hepatitis C. Liver Int. 36:334–343. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Maftouh M, Avan A, Galvani E, Peters GJ
and Giovannetti E: Molecular mechanisms underlying the role of
microRNAs in resistance to epidermal growth factor
receptor-targeted agents and novel therapeutic strategies for
treatment of non-small-cell lung cancer. Crit Rev Oncog.
18:317–326. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rolfo C, Fanale D, Hong DS, Tsimberidou
AM, Piha-Paul SA, Pauwels P, Van Meerbeeck JP, Caruso S, Bazan V,
Cicero G, et al: Impact of microRNAs in resistance to chemotherapy
and novel targeted agents in non-small cell lung cancer. Curr Pharm
Biotechnol. 15:475–485. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gong Z, Yang J, Li J, Yang L, Le Y, Wang S
and Lin HK: Novel insights into the role of microRNA in lung cancer
resistance to treatment and targeted therapy. Curr Cancer Drug
Targets. 14:241–258. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
MacDonagh L, Gray SG, Finn SP, Cuffe S,
O'Byrne KJ and Barr MP: The emerging role of microRNAs in
resistance to lung cancer treatments. Cancer Treat Rev. 41:160–169.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang W, Zhang Y, Zhu B, Duan T, Xu Q, Wang
R, Lu L and Jiao Z: Plasma microRNA expression profiles in Chinese
patients with rheumatoid arthritis. Oncotarget. 6:42557–42568.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shi Y and Huang A: Effects of sorafenib on
lung metastasis in rats with hepatocellular carcinoma: The role of
microRNAs. Tumour Biol. 36:8455–8463. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim JH, Choi YK, Byun JK, Kim MK, Kang YN,
Kim SH, Lee S, Jang BK and Park KG: Estrogen-related receptor γ is
upregulated in liver cancer and its inhibition suppresses liver
cancer cell proliferation via induction of p21 and p27. Exp Mol
Med. 48:e2132016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Thacker PC and Karunagaran D: Curcumin and
emodin down-regulate TGF-β signaling pathway in human cervical
cancer cells. PLoS One. 10:e01200452015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang E, Yin D, Han L, He X, Si X, Chen W,
Xia R, Xu T, Gu D, De W, et al: E2F1-induced upregulation of long
noncoding RNA LINC00668 predicts a poor prognosis of gastric cancer
and promotes cell proliferation through epigenetically silencing of
CKIs. Oncotarget. 7:23212–23226. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huang H and Tindall DJ: Regulation of FOXO
protein stability via ubiquitination and proteasome degradation.
Biochim Biophys Acta. 1813:1961–1964. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang F, Chan CH, Chen K, Guan X, Lin HK
and Tong Q: Deacetylation of FOXO3 by SIRT1 or SIRT2 leads to
Skp2-mediated FOXO3 ubiquitination and degradation. Oncogene.
31:1546–1557. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lu L, Li C, Li D, Wang Y, Zhou C, Shao W,
Peng J, You Y, Zhang X and Shen X: Cryptotanshinone inhibits human
glioma cell proliferation by suppressing STAT3 signaling. Mol Cell
Biochem. 381:273–282. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fernandez S, Risolino M, Mandia N, Talotta
F, Soini Y, Incoronato M, Condorelli G, Banfi S and Verde P:
miR-340 inhibits tumor cell proliferation and induces apoptosis by
targeting multiple negative regulators of p27 in non-small cell
lung cancer. Oncogene. 34:3240–3250. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nam KS, Oh S, Lee KM, Yoo SA and Shin I:
CD44 regulates cell proliferation, migration, and invasion via
modulation of c-Src transcription in human breast cancer cells.
Cell Signal. 27:1882–1894. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang Y, Zhao J, Qiu L, Zhang P, Li J,
Yang D, Wei X, Han Y, Nie S and Sun Y: Co-expression of ILT4/HLA-G
in human non-small cell lung cancer correlates with poor prognosis
and ILT4-HLA-G interaction activates ERK signaling. Tumor Biol.
37:11187–11198. 2016. View Article : Google Scholar
|
|
24
|
Lysov Z, Dwivedi DJ, Gould TJ and Liaw PC:
Procoagulant effects of lung cancer chemotherapy: Impact on
microparticles and cell-free DNA. Blood Coagul Fibrinolysis.
28:72–82. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yongchun Z, Linwei T, Xicai W, Lianhua Y,
Guangqiang Z, Ming Y, Guanjian L, Yujie L and Yunchao H:
MicroRNA-195 inhibits non-small cell lung cancer cell
proliferation, migration and invasion by targeting MYB. Cancer
Lett. 347:65–74. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Koturbash I, Zemp FJ, Pogribny I and
Kovalchuk O: Small molecules with big effects: The role of the
microRNAome in cancer and carcinogenesis. Mutat Res. 722:94–105.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hu J, Qiu M, Jiang F, Zhang S, Yang X,
Wang J, Xu L and Yin R: MiR-145 regulates cancer stem-like
properties and epithelial-to-mesenchymal transition in lung
adenocarcinoma-initiating cells. Tumour Biol. 35:8953–8961. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xu L, Huang Y, Chen D, He J, Zhu W, Zhang
Y and Liu X: Downregulation of miR-21 increases cisplatin
sensitivity of non-small-cell lung cancer. Cancer Genet.
207:214–220. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang M, Li J, Wang L, Tian Z, Zhang P, Xu
Q, Zhang C, Wei F and Chen W: Prognostic significance of p21, p27
and survivin protein expression in patients with oral squamous cell
carcinoma. Oncol Lett. 6:381–386. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Skirnisdottir I and Seidal T: Association
of p21, p21 p27 and p21 p53 status to histological subtypes and
prognosis in low-stage epithelial ovarian cancer. Cancer Genomics
Proteomics. 10:27–34. 2013.PubMed/NCBI
|
|
31
|
Li ZC, Zhang LM, Wang HB, Ma JX and Sun
JZ: Curcumin inhibits lung cancer progression and metastasis
through induction of FOXO1. Tumour Biol. 35:111–116. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shukla S, Rizvi F, Raisuddin S and Kakkar
P: FoxO proteins' nuclear retention and BH3-only protein Bim
induction evoke mitochondrial dysfunction-mediated apoptosis in
berberine-treated HepG2 cells. Free Radic Biol Med. 76:185–199.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bucur O, Stancu AL, Muraru MS, Melet A,
Petrescu SM and Khosravifar R: PLK1 is a binding partner and a
negative regulator of FOXO3 tumor suppressor. Discoveries
(Craiova). 2:pii: e162014. View Article : Google Scholar
|
